Document:

Exhibit 10.16

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

SERVICES AGREEMENT

 

This Services Agreement (“Agreement”) is effective as of June 24, 2005 (“Effective Date”), and made by and between CardioDx, Inc., a Delaware corporation with its principal place of business at 3183 Porter Drive, Palo Alto, CA, 94304 (“CardioDx”), and XDx, Inc., a Delaware corporation having its principal place of business at 750 Gateway Boulevard, South San Francisco, CA 94080 (“XDx”), shall govern the terms and conditions of the transfer of tangible samples and/or chemical or biological materials by XDx to CardioDx.

 

WHEREAS XDx has expertise in biological studies and genetic analysis, and has collected certain biological samples and data related thereto;

 

WHEREAS CardioDx desires to obtain those samples and related data, and have XDx perform certain services related thereto;

 

NOW THEREFORE, for good and valuable consideration, the sufficiency of which is acknowledged, and in consideration of the promises and mutual covenants contained in this Agreement, the parties agree as follows:

 

1)                                     Definitions.

 

(a)                                 “Data” means the patient data, information, clinical data and other records or results in XDx’s possession or control relating to each sample of Material.

 

(b)                                 “Field of Use” means the diagnosis of coronary artery disease (CAD); excluding the diagnosis of patients who have undergone transplants of any type and/or the diagnosis of patients with previously diagnosed co-morbidities of lupus and/or rheumatoid arthritis.  For purposes of clarification, CardioDx may not market, make claims, promote, or label Licensed Products outside the Field of Use.

 

(c)                                  “CardioDx Intellectual Property Rights” means patent rights, copyright rights, utility models rights, trade secret rights, trademark rights, rights of publicity, authors’ rights, contract and licensing rights, goodwill and all other intellectual property rights owned or controlled by CardioDx, as may exist now and/or hereafter come into existence during the term of this Agreement and for a three year period thereafter, and all applications therefor and registrations, continuations, continuations-in-part, divisions, reissues, reexaminations, renewals and extensions thereof, regardless of whether such rights arise under the laws of the United States or any other state, country or jurisdiction, to the extent made by CardioDx or its affiliates, consultants, employees, or collaborators with the use of the Material or Data.

 

(d)                                 “XDx Intellectual Property Rights” means patent rights, copyright rights, utility models rights, trade secret rights, trademark rights, rights of publicity, authors’ rights, contract and licensing rights, goodwill and all other intellectual property rights owned or controlled by XDx, as may exist now and/or hereafter come into existence during the term of this Agreement and for a three year period thereafter,

 

1

 

and all applications therefor and registrations, continuations, continuations-in-part, divisions, reissues, reexaminations, renewals and extensions thereof, regardless of whether such rights arise under the laws of the United States or any other state, country or jurisdiction, to the extent made by XDx or its affiliates, consultants, employees, or collaborators with the use of the Material or Data.  For purposes of clarification, as of the Effective Date of this Agreement, XDx does not own or control any patents or patent applications made with the use of the Material or Data.

 

(e)                                  “Licensed Product” means any product or service, in the Field of Use, covered by CardioDx Intellectual Property Rights.

 

(f)                                   “Material” means those tangible biological materials in XDx’s possession or control retained in connection with the study, as further described on Exhibit A.

 

(g)                                  “Net Sales” means the gross amount received by CardioDx or its affiliates or sublicensees from the sale of Licensed Products to an unaffiliated third party, less the following:

 

i)                                         customary trade, quantity or cash discounts to the extent actually allowed and taken;

 

ii)                                      amounts repaid or credited by reason of rejection or return;

 

iii)                                   to the extent separately stated on purchase orders, invoices or other documents of sale, any taxes or other governmental charges levied on the sale, transportation, delivery or use of a Licensed Product which is paid by or on behalf of CardioDx; and

 

iv)                                  outbound transportation costs prepaid or allowed and costs of insurance in transit.

 

(h)                                 “Sample” means one (1) CPT tube of the Material collected from a particular study subject.

 

(i)                                     “Territory” means worldwide.

 

2)                                     License Grant.  XDx hereby grants to CardioDx a perpetual, worldwide license, under the XDx Intellectual Property Rights, to (i) use and modify the Data and Materials, and (ii) make, have made, modify, use, offer for sale, sell, distribute and import Licensed Product(s), all solely in the Field of Use and in the Territory.  The foregoing license shall be exclusive for a period of two (2) years from the Effective Date (“Exclusive Period”) and nonexclusive thereafter (“Nonexclusive Period”).  XDx shall at all times retain the rights to the Data and Materials to make, have made, use, and sell products and services covered by XDx Intellectual Property Rights (“XDx Products”) in all fields (including the Field of Use).  CardioDx grants to XDx a perpetual, worldwide, non-exclusive, royalty free license to make, have made, modify, use, offer for sale, sell, distribute and

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

2

 

import XDx Products covered by CardioDx Intellectual Property Rights.

 

3)                                     Delivery Of Material And Data.

 

(a)                                 XDx shall deliver or cause to be delivered to CardioDx, within thirty (30) days after the Effective Date, all of the Data.

 

(b)                                 XDx shall perform the services described in Section 4 below on the Samples identified by CardioDx (with XDx’s assistance) as described in Exhibit A.

 

(c)                                  CardioDx shall reimburse XDx for the reasonable expenses it incurs to properly package and deliver the Material and Data requested by CardioDx.

 

4)                                     Services.

 

(a)                                 Within 30 days of receipt of a written request from CardioDx, XDx shall extract RNA from the tube of Material from those Samples specified by CardioDx (each, an “RNA Extraction”) and deliver the same to CardioDx.  In addition, XDx shall perform capillary electrophoresis on the extracted RNA if specified in the written request from CardioDx.  The results of the electrophoresis will be delivered to CardioDx along with the RNA Extraction.

 

(b)                                 CardioDx and XDx shall work together to define the Samples of interest to be listed in Exhibit A.  XDx shall provide to CardioDx extracted RNA from one (1) CPT tube per Sample and all relevant data.

 

(c)                                  For RNA Extraction, CardioDx shall stipulate the amount of RNA to be delivered per Sample as defined in Exhibit B.  XDx will provide to CardioDx this stipulated amount of RNA or the entire amount of RNA extracted if the amount of RNA extracted from a Sample is below the stipulated amount.

 

5)                                     Consideration.

 

(a)                                 License Fee.  In consideration for the provision of the Data and Material, and the licenses set forth herein, CardioDx shall pay XDx a one-time, non-refundable license fee of [... * ...] within thirty (30) days of the Effective Date.

 

(b)                                 Royalties.  In consideration for the provision of the Data and Material, and the licenses set forth herein, CardioDx shall pay to XDx a running royalty of [... * ...] of Net Sales of Licensed Products.  In the event that CardioDx is required to pay royalties to any third party in connection with the manufacture, use, sale or commercialization of Licensed Products, then CardioDx may set off [... * ...] of the amount of such royalties against royalties payable to XDx; provided, however, that in no event will the royalty owing to XDx be reduced below [... * ...] of Net Sales.  CardioDx’s payment obligations under this Section 5 shall terminate on the tenth (10th) anniversary of the first commercial sale of a Licensed Product by CardioDx.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

3

 

6)                                     Payment for Services. CardioDx shall pay XDx the following services fees: (a) [... * ...] per Sample chosen by CardioDx from which XDx performs an RNA Extraction for CardioDx, as defined in Exhibit A; or (b) [... * ...] per Sample chosen by CardioDx from which XDx performs both an RNA Extraction and capillary electrophoresis for CardioDx, as defined in Exhibit A. These services payments shall be paid within thirty (30) days of the end of each calendar month in which samples are chosen.

 

7)                                     Ownership.  CardioDx shall exclusively own the CardioDx Intellectual Property Rights. XDx shall exclusively own the XDx Intellectual Property Rights.  Within three (3) months of CardioDx’s acquiring any data analysis of the Samples, CardioDx shall provide XDx with any raw array data from that analysis (“Array Data”).  Six (6) months from the Effective Date of this Agreement and on each three (3) month anniversary thereafter, CardioDx shall provide XDx all additional patient data, information, clinical data and other records or results in CardioDx’s possession or control relating to each sample of Material (“Additional Data”).  The Array Data and the Additional Data may be used by XDx to develop XDx Products during the Exclusive Period, subject to the terms and conditions of Section 8 and any other applicable provision in this Agreement.  During the Nonexclusive Period, XDx may use the Array Data and the Additional Data without limitation, subject to terms and conditions of Section 8.

 

8)                                     Confidentiality.

 

(a)                                 “Confidential Information” of a party means any information disclosed by such party to the other party pursuant to this Agreement, which is in written, graphic, machine readable or other tangible form and is marked “Confidential,” “Proprietary” or in some other manner to indicate its confidential nature, or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and reduced to writing within thirty (30) days of such disclosure, and such writing is marked in a manner to indicate its confidential nature and delivered to the receiving party.  Notwithstanding any failure to so mark it, the Material and Data shall be deemed Confidential Information of XDx, and the Array Data and Additional Data shall be deemed Confidential Information of CardioDx.

 

(b)                                 For a period of five (5) years after disclosure of any portion of Confidential Information the receiving party shall (i) maintain such Confidential Information in strict confidence, except that the receiving party may disclose or permit disclosure of any Confidential Information to its directors, officers, employees, consultants, auditors, and advisors who are obligated to maintain the confidential nature of such Confidential Information and who need to know such Confidential Information for the purposes of this Agreement; (ii) use such Confidential Information solely for the purposes of this Agreement; and (iii) allow its directors, officers, employees, consultants, auditors, and advisors to reproduce the Confidential Information only to the extent necessary for the purposes of this Agreement with all such reproductions being considered Confidential

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

4

 

Information.

 

(c)                                  The obligations of the receiving party under Section 8(b) shall not apply to the extent that the receiving patty can demonstrate that certain Confidential Information:  (i) was generally available to the public prior to the time of its disclosure under this Agreement; (ii) was generally available to the public after the time of its disclosure under this Agreement through means other than an unauthorized disclosure resulting from an act or omissions by the receiving party; (iii) was independently developed or discovered by the receiving party without use of the Confidential Information; (iv) is or was disclosed to the receiving party at any time, whether prior to or after the time of its disclosure under this Agreement, by a third party having no fiduciary relationship with the disclosing party and having no obligation or confidentiality with respect to such Confidential Information; or (v) is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative order provided that the disclosing party receives reasonable prior written notice of such disclosure.

 

9)                                     No Warranty.  THE MATERIALS AND THE DATA ARE BEING SUPPLIED WITH NO WARRANTIES, EXPRESS OR IMPLIED, AND XDX EXPRESSLY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT,

 

10)                              Care in Use of Materials.  CardioDx shall be entitled to rely on the written representations and instructions (if any) of XDx regarding the use, handling, storage, transportation or other disposition or containment of the Materials.

 

11)                              Limitation of Liability.  IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, OR LOSS OF PROFITS, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.  THE FOREGOING LIMITATIONS SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

 

12)                              No Conflict.  XDx and CardioDx each represent to the other that this Agreement does not, and during the term of this Agreement, will not conflict with any other right or obligation provided under any other agreement or obligation that it has with any third party.

 

13)                              Term and Termination.

 

(a)                                 Term. This Agreement will commence on the Effective Date and remain in effect until terminated in accordance with this Section 13.  At any time after the second anniversary of the Effective Date, either party may terminate this Agreement upon written notice to the other party.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

5

 

(b)                                 Termination for Material Breach and Certain Other Events.  Either party may terminate this Agreement immediately by written notice to the other party if the other party materially breaches any of the provisions of this Agreement, and such material breach is not cured within thirty (60) days after written notice thereof to the party in breach.  Either party shall have the right to terminate this Agreement, immediately by written notice to the other party, if the other party:  (i) ceases to carry on its business related to this Agreement; (ii) files or has filed against it a petition under bankruptcy law, a corporate reorganization law or any other law for the relief of debtors or similar law analogous in purpose or effect, and such petition is not resolved in favor of the other party within ninety (90) days after the filing of the same; (iii) makes an assignment for the benefit of creditors; or (iv) enters into liquidation or dissolution proceedings or a receiver is appointed with respect to any of its assets.

 

(c)                                  Survival.  Sections 2, 5 and 7-14, together with any accrued but unpaid payment obligations, shall survive any termination or expiration of this Agreement.

 

14)                              General.

 

(a)                                 Entire Agreement.  This Agreement contains the entire agreement between the parties with respect to the subject matter hereof, and supersedes any prior agreements, negotiations or representations between the parties with respect to the subject matter hereof, whether written or oral.

 

(b)                                 Modification.  This Agreement may be modified only by a subsequent written agreement signed by the parties.

 

(c)                                  Severability.  If any provision of this Agreement is held to be unenforceable, the remaining provisions shall continue unaffected.

 

(d)                                 Waiver.  None of the terms, covenants, and conditions of this Agreement can or will be waived except by the written consent of the party waiving compliance.

 

(e)                                  Agency.  The parties do not intend that any agency or partnership relationship be created between them by this Agreement.

 

(f)                                   Assignment.  This Agreement, and any rights or obligations hereunder, may not be assigned, transferred or delegated in whole or in part by either party, except with the other party’s express written approval; provided, however, that no consent shall be required for any assignment in connection with a merger, acquisition, reorganization or transfer of all or substantially all of the stock, assets or business to which this Agreement relates.

 

(g)                                  Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of California, U.S.A. applicable to contracts

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

6

 

entered into and wholly to be performed within the State of California by California residents (regardless of the choice of law principles of California or any other jurisdiction).  Each party hereby consents to the exclusive jurisdiction of the state and federal courts located in Santa Clara County, California, with respect to any dispute arising out of or relating to this Agreement.

 

(h)                                 Notices.  Any notice required or permitted hereunder shall be in writing and shall be deemed effectively given upon personal delivery, five business days after deposit if sent by certified mail, postage prepaid, return receipt requested, or the day after delivery to a recognized overnight courier, to the following addresses:

 

If to CardioDx:

 

CardioDx
 3183 Porter Drive
 Palo Alto, CA 94304

 

Attention: President and Chief Executive Officer

 

If to XDx:

 

750 Gateway Boulevard
 South San Francisco, CA 94080

 

Attention: President and Chief Executive Officer

 

[signature page follows]

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

7

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed below.

 

 

	
CardioDx, Inc.
    	
XDx, Inc.
    
	
 
    	
 
    
	
By:
    	
/s/   David Levison
    	
 
    	
By:
    	
/s/   Pierre G. Cassigneul
    
	
 
    	
(Signature)
    	
 
    	
(Signature)
    
	
 
    	
 
    
	
 
    	
David   Levison
    	
 
    	
 
    	
Pierre   G. Cassigneul
    
	
 
    	
(Printed Name)
    	
 
    	
(Printed Name)
    
	
 
    	
 
    
	
 
    	
President &   CEO
    	
 
    	
 
    	
CEO,   President
    
	
 
    	
(Title)
    	
 
    	
(Title)
    
	
 
    	
 
    
	
 
    	
7-5-05
    	
 
    	
 
    	
6/24/2005
    
	
 
    	
(Date)
    	
 
    	
(Date)
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

8

 

Exhibit A

 

Materials to be Transferred

 

	
Sample ID
    	
Date Requested
    	
Capillary
   Electrophoresis to be
   Performed (Yes/No)
    	
Service Fee
    
	
17-0001
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0002
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0004
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0005
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0007
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0008
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0012
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0013
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0016
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0018
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0020
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0021
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0027
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0030
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0031
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0032
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0033
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0034
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0037
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0040
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0041
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0048
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0050
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0051
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0057
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0058
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0061
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0062
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0064
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0065
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0066
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0069
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0071
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0074
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0075
    	
7/14/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

9

 

	
17-0077
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0083
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0087
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0093
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0094
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0095
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0627
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0629
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0630
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0635
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0640
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0644
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0645
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0647
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0648
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0650
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0652
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0653
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0655
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0657
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0658
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0660
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0661
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0662
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0670
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0672
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0673
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0674
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0675
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0679
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0680
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0681
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0683
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0685
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0686
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0689
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0691
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0692
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0693
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0697
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0702
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0703
    	
7/7/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

10

 

	
17-0706
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0707
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0708
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0709
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0711
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0714
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0715
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0719
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0726
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0730
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0731
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0732
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0733
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0734
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0735
    	
7/7105
    	
Yes
    	
[... * ...]
    
	
17-0737
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0741
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0747
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0748
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0749
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0750
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0752
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0753
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0755
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0756
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0758
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0759
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0765
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0767
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0768
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0775
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0776
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0777
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0783
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0784
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0785
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17 0787
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0790
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0791
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0792
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0793
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0796
    	
7/14/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

11

 

	
17-0802
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0804
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0805
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0810
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0811
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0812
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0813
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0818
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0820
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0822
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0823
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0826
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0827
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0828
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0829
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0830
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0831
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0832
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0833
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0836
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0840
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0841
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0842
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0848
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0850
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0851
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0854
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0856
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0857
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0860
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0862
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0863
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0864
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0869
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0870
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0872
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0873
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0874
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0875
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0876
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0877
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0878
    	
7/14/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

12

 

	
17-0881
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0883
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0886
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0889
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0890
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0892
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0897
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0899
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0903
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0904
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0905
    	
7/7/05
    	
Yes
    	
[... * ...]
    
	
17-0907
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0908
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0909
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
170910
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0915
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0917
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0920
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0921
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0923
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0924
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0925
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0929
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0933
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0939
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0940
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0943
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0944
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0947
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0948
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0950
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0951
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0954
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0956
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0957
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0958
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0960
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0962
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0963
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0967
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0970
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0976
    	
7/14/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

13

 

	
17-0978
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0979
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0980
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0985
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0989
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0993
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0994
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-0998
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1002
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1005
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1008
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1013
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1016
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1019
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1022
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1029
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1031
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1035
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1036
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1038
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1041
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1042
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1047
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1050
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1051
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1052
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1054
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1055
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1056
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1063
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1068
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1069
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1073
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1074
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1075
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1076
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1077
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1083
    	
7/14/05
    	
Yes
    	
[... * ...]
    
	
17-1086
    	
7/14/05
    	
Yes
    	
[... * ...]
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

14

 

Exhibit B

 

CardioDx RNA Specifications

 

Amount of extracted RNA to be transferred:  5 μg per Sample

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

15Exhibit 10.17

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

PATENT LICENSE AGREEMENT

 

(Human Diagnostic Services)

 

CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Background
    	
 
    	
2
    
	
 
    	
 
    	
 
    
	
Section 1
    	
Definitions
    	
3
    
	
 
    	
 
    	
 
    
	
Section 2
    	
Grant
    	
5
    
	
 
    	
 
    	
 
    
	
Section 3
    	
Additional   Limitations and Acknowledgment re Diagnostic Products
    	
6
    
	
 
    	
 
    	
 
    
	
Section 4
    	
Royalties,   Records and Reports
    	
6
    
	
 
    	
 
    	
 
    
	
Section 5
    	
Technology   Notification
    	
8
    
	
 
    	
 
    	
 
    
	
Section 6
    	
Diligence
    	
8
    
	
 
    	
 
    	
 
    
	
Section 7
    	
Term   and Termination
    	
8
    
	
 
    	
 
    	
 
    
	
Section 8
    	
Confidentiality-Publicity
    	
10
    
	
 
    	
 
    	
 
    
	
Section 9
    	
Compliance
    	
11
    
	
 
    	
 
    	
 
    
	
Section 10
    	
Assignment
    	
11
    
	
 
    	
 
    	
 
    
	
Section 11
    	
Negation   of Warranties and Indemnity
    	
12
    
	
 
    	
 
    	
 
    
	
Section 12
    	
General
    	
12
    

 

	
Attachments:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Attachment   I
    	
List   of Licensed Technology
    	
 
    
	
 
    	
 
    	
 
    
	
Attachment   II
    	
Combination   Services
    	
 
    
	
 
    	
 
    	
 
    
	
Attachment   III
    	
Summary   Royalty Report Form
    	
 
    
	
 
    	
 
    	
 
    
	
Attachment   IV
    	
Collection   Rate
    	
 
    

 

 

PATENT LICENSE AGREEMENT

 

(Human)

 

This Agreement is made by and between

 

Roche Molecular Systems, Inc., 4300 Hacienda Drive, Pleasanton, California 94588

(hereafter referred to as “RMS”)

 

and

 

CardioDx, Inc., 2500 Faber Place, Palo Alto, California 94303

(hereafter referred to as “LCE”)

 

hereafter individually referred

to as a “Party” or collectively as “The Parties”

 

********

 

BACKGROUND

 

A.                                          RMS owns and has the right to grant licenses to practice under certain United States Patents describing and claiming, inter alia, nucleic acid amplification processes known as polymerase chain reaction (“PCR”), homogeneous PCR, and RT-PCR (“reverse transcription PCR”).

 

B.                                          LCE desires to obtain a non-exclusive license from RMS to use the Licensed Technology to perform certain PCR-based human, in vitro clinical laboratory services, and RMS is willing to grant such a license to LCE on the terms and subject to the conditions provided exclusive in this Agreement.

 

NOW, THEREFORE, for and in consideration of the mutual covenants contained herein, RMS and LCE agree as follows:

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

2

 

1.                                      Definitions

 

For the purpose of this Agreement, and solely for that purpose, the terms set forth hereinafter shall be defined as follows:

 

1.1                               The term “Affiliate” shall mean with respect to a given Party:

 

a)                                     an organization which, directly or indirectly, controls such party;

 

b)                                     an organization which is, directly or indirectly, controlled by such Party; or

 

c)                                      an organization which is controlled, directly or indirectly, by the ultimate parent company which controls, directly or indirectly, such Party.

 

For purposes of this paragraph, “control” shall mean the ownership of fifty percent (50%) or more of the voting stock or equity interests of an organization or otherwise having the power to govern or direct the financial and the operating policies or to appoint the management of such organization.

 

With respect to RMS, the term “Affiliate” shall not include Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A. (“Genentech”) nor Chugai Pharmaceutical Co., Ltd, 1-9, Kyobashi 2-chome, Chuo-ku, Tokyo, 104-8301 Japan (“Chugai”), unless and until RMS notifies LCE in writing that one or both of such entities are to be included as an Affiliate of RMS.

 

1.2                               “Combination Service” shall mean a Licensed Service offered in combination with a non-Licensed Technology based test and/or together with a non-testing service(s) such as a specialized interpretive service or a consultative service (e.g., genetic counseling) as part of a package, where the Licensed Service is not separately billed.

 

1.3                               “Diagnostic Product” shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

 

1.4                               “Effective Date” shall mean the date on which the last signatory to this Agreement signs this Agreement.

 

1.5                               “Licensed Field” shall mean the field of clinical laboratory services that detect the presence, absence and/or quantity of a nucleic acid sequence for the detection, diagnosis, confirmation, prognosis, management and/or treatment of a human disease or condition, including, but not limited to, such services: to identify predisposition to disease, disease susceptibility, confirm disease, predict therapeutic effectiveness or monitor disease progress; used in the course of human clinical trials related to diagnostic products; and for tissue transplant typing, including testing performed on animal tissue intended for use in

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

3

 

xenotransplantation.  Licensed Field shall specifically exclude any services performed for the screening of blood and/or blood products.

 

1.6                               “Licensed Service(s)” shall mean the performance by LCE of an in vitro procedure within the Licensed Field which utilizes the Licensed Technology.  Licensed Services include, but are not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences from the sample, amplifying one or more desired sequences, analyzing the amplified material, including sequence analysis, and reporting the results.

 

1.7                               “Licensed Technology” shall mean, subject to the following limitations, the Valid Claims of the United States patents listed in Attachment I to this Agreement and any reissue or reexamination patents thereof.  No rights under any kit claims of such patents are included in this definition or licensed under this Agreement.  With the exception of the reaction mixture claims of United States Patents Nos. 5,804,375, 5,693,517, 5,476,774 and 6,127,155, the plasmid claims of the 5,476,774 patent, the primer claims of United States Patent No. 5,573,906, and the probe claims of United States Patent No. 5,110,920, no rights under any apparatus, device, composition of matter, reagent or substance claims of such patents are included in this definition or licensed under this Agreement.

 

1.8                               “Net Service Revenues” shall mean the gross invoice price for the Licensed Services performed by LCE (or the fair market value for any nonmonetary consideration which LCE agrees to receive in exchange for Licensed Services), less the following deductions where they are factually applicable and are not already reflected in the gross invoice price:

 

a)                                     discounts allowed and taken, in amounts customary in the trade (which shall include the difference between the dollar amount charged by LCE for a Licensed Service and the Medicare and/or Medicaid Limits of Allowance and/or reimbursement limitations of a Third Party insurance program); and

 

b)                                     actual bad debt which bad debt LCE can prove and document that it was reasonable and diligent in its efforts to collect payment.

 

1.8.1                     The Net Service Revenues of those Licensed Services that are performed by LCE for any person, firm or corporation controlling, controlled by or under common control with LCE, or enjoying a special course of dealing with LCE, shall be determined based on the average selling price of such Licensed Services to all Third Parties during the period in question.

 

1.8.2                     It is hereby understood and agreed that, to the extent feasible, Licensed Services and Combination Services shall at all times be invoiced, listed and billed by LCE as a separate item in LCE’s invoices, bills and reports to customers.  Net Service Revenues for determining royalties with respect to a Licensed Service which is part of a Combination Service shall be determined by multiplying the gross invoice price of the Combination Service, less applicable deductions, by the appropriate fraction in Attachment II hereto.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

4

 

The fraction specified in Attachment II for a particular Licensed Service included in a Combination Service shall be set by RMS after consultation with LCE, as accurately reflecting the value contributed by the Licensed Service to the overall value of the Combination Service as offered by LCE, and as provided in Section 2.4.  Attachment II hereto shall be modified as new Combination Services are identified and new royalty-bearing fractions set, and as set forth in Section 2.4.

 

1.9                               “Territory” shall mean the United States and its possessions and the Commonwealth of Puerto Rico.

 

1.10                        “Third Party” shall mean an entity other than an Affiliate of either Party to this Agreement.

 

1.11                        “Valid Claim” shall mean a claim of a patent which has not expired or been disclaimed, cancelled, held invalid or held unenforceable by a decision of a court or other governmental agency of competent jurisdiction, from which no further appeal is possible or has been taken within the time period provided under applicable law for such an appeal.

 

2.                                      Grant

 

2.1                               Grant.  Upon the terms and subject to the conditions and restrictions of this Agreement, RMS hereby grants to LCE, and LCE hereby accepts from RMS, a royalty-bearing, non-exclusive, personal, non-transferable license under the Licensed Technology solely to perform Licensed Services within the Territory.

 

2.2                               Performance of Licensed Services Only.  The Licensed Technology may be used solely for the performance of Licensed Services and for no other purpose whatsoever, and no other right, immunity or license is granted to LCE expressly, impliedly or by estoppel.

 

2.3                               Personal License.  LCE expressly acknowledges and agrees that the license granted hereunder is personal to LCE alone and LCE shall have no right to sublicense, assign or otherwise transfer or share its rights under the foregoing license.

 

2.4                               Combination Service(s).  For each Combination Service that LCE intends to offer pursuant to this Agreement, and at least sixty (60) days before LCE intends to offer any such Combination Service, LCE shall:

 

a)                                     notify RMS of such proposed Combination Service, such notice to include a complete and detailed description of the proposed Combination Service; and

 

b)                                     obtain from RMS a duly authorized agreement, in the form of Attachment II hereto, for such Combination Service, which agreement shall indicate the fraction or percentage of the package price of such Combination Service, less appropriate deductions, on which royalties shall be paid hereunder.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

5

 

For any Combination Service(s) for which LCE has not satisfied the criteria set forth in subsections (a) and (b) above, the royalty payable on such Combination Service shall be assessed on 100% of the package price of such Combination Service, less applicable deductions.  As to all other Licensed Services offered by LCE which are not part of a Combination Service, LCE agrees to inform RMS of the availability from FLCE of each such Licensed Service within thirty (30) days after LCE commences offering the Licensed Service.

 

2.5                               Credit for Licensed Technology Rights.  RMS hereby grants to LCE the right and LCE accepts and agrees to credit RMS as the source of its Licensed Technology rights in LCE’s promotional materials and any other materials intended for distribution to Third Parties as follows:

 

“This service is performed pursuant to an agreement with Roche Molecular Systems, Inc.”

 

3.                                      Additional Limitations and Acknowledgment Regarding Diagnostic Products

 

LCE acknowledges and agrees that the license rights granted hereunder are for the performance of Licensed Services only and do not include any right to make, have made, import, offer to sell or sell any products, including apparatuses, devices, PCR reagents, kits or Diagnostic Products.  LCE further acknowledges and agrees that RMS and its Affiliates are in the business of providing clinical laboratory testing services and the commercial sale of diagnostic testing systems, kits and reagents and therefore may compete directly with LCE’s business.

 

4.                                      Royalties, Records and Reports

 

4.1                               Royalties.  For the rights and privileges granted under Section 2.1 of this Agreement, LCE shall pay to RMS royalties equal to [... * ...] of LCE’s Net Service Revenues.

 

No royalty is due on PCR-based assays performed solely for the purpose of evaluating a procedure to be used as a Licensed Service after validation).

 

No royalty is due on assays performed with Roche labeled diagnostic kits or Third Party diagnostics kits licensed by Roche, which convey human diagnostic label license rights to end users.

 

4.2                               Reports.  LCE shall deliver to RMS, within forty-five (45) days after the end of and for each quarterly calendar period during the Term, i.e. the three (3) month periods that are January 1 through March 31, April 1 through June 30, July 1 through September 30, and October 1 through December 31 (each a “Reporting Period”), a true and accurate royalty report (“Royalty Report”).  Each Royalty Report shall indicate the number of Licensed Services performed during the relevant Reporting Period and the detail specified on the “Summary Royalty Report,” a copy of which is attached hereto as Attachment III, or on a form generated by LCE which duplicates the format of the Summary Royalty Report.  If no royalties are due for a given Royalty Period, it shall be so reported.  The correctness and

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

6

 

completeness of each Royalty Report shall be attested to in writing by an authorized representative of LCE.

 

In the event LCE is unable to calculate Net Service Revenues as prescribed in Section 1.8, LCE shall so inform RMS, and upon RMS’s written consent, LCE shall calculate royalties as follows:

 

Upon receipt by RMS of satisfactory documentation verifying LCE’s actual percentage of gross billings for Licensed Services and/or Combination Services collected for LCE’s most recently ended fiscal year (the “Collection Rate”), subject to the provisions of Section 2.4 above, LCE shall be permitted to calculate Net Service Revenues taking into account the Collection Rate.  As of the Effective Date, LCE hereby represents and confirms to RMS that its Collection Rate for its fiscal year ending  NA  was  NA  percent ( NA %), which rate is specified in Attachment IV.  During the Term of this Agreement, and within ninety (90) days after the end of each LCE fiscal year, LCE shall deliver to RMS satisfactory documentation that verifies the then Collection Rate.  If LCE’s Collection Rate varies by at least five percent (5%) from the rate stated in Attachment IV, RMS shall amend Attachment IVV accordingly.  Should LCE fail to provide the required updated documentation, LCE shall calculate Net Service Revenues and royalties due as prescribed in Sections 1.8 and 2.4 for the remaining Term of the Agreement.

 

Simultaneously with the delivery of each Royalty Report, LCE shall pay to RMS the royalty due under this Agreement for the period covered by such report.  All payments due RMS hereunder shall be payable in United States currency and sent together with the Royalty Report by the due date to the following address:

 

Roche Molecular Systems, Inc.

P.O. Box 120216

Dallas, Texas 75312-0216

 

or to any other address that RMS may advise in writing.

 

4.3                               Inspection.  Within ten (10) days after RMS’s written request to LCE, an accounting firm selected by RMS (including, but not limited to, RMS’s normal certified public accounting firm), may, at RMS’s own expense (except as provided below), inspect the records, books of account and any other materials of LCE pertaining to the transactions and matters contemplated by this Agreement and/or the Royalty Reports required in Section 4.2 above, provided that any accounting firm will hold such records in strict confidence, except as necessary to report to RMS and LCE on LCE’s compliance with the terms, conditions and restrictions of this Agreement.  If such an inspection shows an underpayment by LCE to RMS by more than ten percent (10%) for any Reporting Period, LCE will pay, in addition to the amount due, plus interest, the accounting firm’s reasonable fees and expenses.

 

4.4                               Prior Licensed Services.  Licensed Services performed by LCE prior to execution of this Agreement shall be subject to the royalties described in this Agreement and shall be reported and due to RMS with the first Royalty Report due provided under Section 4.2; provided,

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

7

 

however, that where this Agreement replaces an existing license agreement, the royalty obligations of LCE under this Agreement commence the first day of the month in which this Agreement is executed.

 

4.5                               Past Due Amounts Bear Interest.  If LCE shall fail to pay any amount specified under this Agreement by the due date thereof, the amount owed shall bear interest at the lower of (i) the Citibank, N.A. base lending rate (aka, the “Prime Rate”), or (ii) the maximum rate allowed by applicable law, from the due date until paid.

 

4.6                               Survival.  The provisions of this Section 4 shall survive any termination or expiration of this Agreement.

 

5.                                      Technology Notification

 

5.1                               Notification.  With respect to any invention, improvement or discovery (hereinafter referred to as “Discoveries” in this Section) of LCE made after entering into this Agreement and resulting from work conducted under or in conjunction with this Agreement and being applicable to the Licensed Technology, if LCE decides to license said Discoveries to Third Parties, then LCE agrees to provide to RMS, unless not possible due to LCE’s pre-existing commitments to Third Parties relating to said Discoveries, a reasonable opportunity to negotiate a license to use said Discoveries in PCR-based Diagnostic Products and services.  Such Discoveries may include, but are not limited to, improvements of the Licensed Technology or in the performance of Licensed Services, modifications to or new methods of performing the Licensed Services, including the automation of the PCR process or of the Licensed Services.

 

5.2                               Agreement re Discovery.  Any agreement reached between The Parties as a result of LCE’s notification to RMS of a Discovery pursuant to Section 5.1 hereto shall be upon terms and conditions negotiated in good faith by The Parties.

 

6.                                      Diligence

 

LCE shall exercise reasonable diligence in developing, testing, validating, documenting, promoting and performing the Licensed Services.  In the course of such diligence, LCE shall implement appropriate procedures and take appropriate steps including, upon reasonable written request of RMS, furnishing RMS with representative copies of all promotional material relating to the Licensed Services.

 

7.                                      Term and Termination

 

7.1                               Term of Agreement.  This Agreement shall commence on the Effective Date and, unless terminated earlier as provided herein, shall terminate on the date of expiration of the last to expire of the patents included within the Licensed Technology, which patent contains at least one Valid Claim covering the performance of a Licensed Service.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

8

 

7.2                               LCE Termination for Convenience.  Notwithstanding any other Section of this Agreement, LCE may terminate this Agreement for any reason on thirty (30) days’ written notice to RMS.

 

7.3                               Termination for Change of Control, Etc.  RMS shall have the right to terminate this Agreement and the license rights granted herein immediately upon written notice to LCE upon any material change in the ownership or control of LCE or of its assets or in the event LCE breaches the provisions of Section 10 below.

 

7.4                               Termination for Insolvency, Etc.  This Agreement and the license rights granted hereunder to LCE shall automatically terminate upon:  (a) an adjudication of LCE as bankrupt or insolvent, or LCE’s admission in writing of its inability to pay its obligations as they mature; or (b) an assignment by LCE for the benefit of creditors; or (c) LCE’s applying for or consenting to the appointment of a receiver, trustee or similar officer for any substantial part of its business or property, or such a receiver, trustee or similar officer’s appointment without the application or consent of LCE, if such appointment shall continue in effect for a period of ninety (90) days; or (d) LCE’s instituting (by petition, application, answer, consent or otherwise) any bankruptcy, insolvency arrangement or similar proceeding relating to LCE or its business or property under the laws of any jurisdiction; or (e) the institution of any such proceeding (by petition, application, answer, consent or otherwise) against LCE, if such proceeding shall remain in effect for a period of ninety (90) days; or (f) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against a substantial part of the property of LCE, if such judgment, writ, or similar process shall not be released, vacated or fully bonded within ninety (90) days after its issue or levy; or (g) the loss of LCE’s federal or state licenses, permits or accreditation necessary for the operation of LCE as a health care institution; provided, however, if loss of any such license, permit or accreditation is due solely to LCE’s failure to make a payment relating thereto, the LCE shall have a thirty (30) day cure period in which to make such payment and thereby restore such license, permit or accreditation.

 

7.5                               Termination for Breach.  Upon any breach of or default by LCE of a material term under this Agreement, RMS may terminate this Agreement upon thirty (30) days’ written notice to LCE. Said termination shall become effective at the end of the thirty-day period, unless during said period LCE fully cures such breach or default.

 

7.6                               Effects of Termination.  Upon termination of this Agreement as provided herein, all license rights and immunities granted to LCE hereunder shall terminate and revert to or be retained by RMS.  To the extent RMS has licensed technology or know-how of LCE pursuant to Section 5 hereto; those licenses shall remain in force according to their terms.  Other provisions of this Agreement which by their nature would reasonably be expected to survive termination shall so survive.  Termination of this Agreement shall not relieve either Party from any duty or obligation that had accrued prior to termination.  Each Party shall retain all of its rights and remedie4s in respect of any breach or default by the other party of the terms, conditions and provisions of this Agreement.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

9

 

7.7                               Duty to Report and Pay Royalties Survives.  LCE’s obligations to report to any pay royalties to RMS as to the Licensed Services performed under the Agreement prior to termination or expiration of the Agreement shall survive such termination or expiration.

 

8.                                      Confidentiality-Publicity

 

8.1                               Publicity.  Except as otherwise specifically provided in Section 2.5, LCE agrees to obtain RMS’s written approval before distributing any written information, such as a press release, to Third Parties which contains references to RMS or this Agreement.  RMS’s approval shall not be unreasonably withheld or delayed and, in any event, RMS’s decision shall be rendered within three (3) weeks of receipt of the written information.  Once approved, such materials, or abstracts of such materials, which do not materially alter the context of the material originally approved may be reprinted during the Term of the Agreement without further approval by RMS unless RMS has notified LCE in writing of its decision to withdraw permission for such use.

 

8.2                               Confidentiality Obligations.  Each party agrees that any financial, legal or business information or any technical information marked “Confidential” or “Proprietary” and disclosed to it (the “Receiving party”) by the other (the “Disclosing Party”) in connection with this Agreement, shall be considered the confidential and proprietary information of the Disclosing Party, and the Receiving Party shall not disclose same to any Third Party and shall hold it in confidence for a period of five (5) years and will not sue it other than in the performance of this Agreement, provided, however, that any information, know-how or data which is orally disclosed to the Receiving Party shall not be considered confidential and proprietary unless such oral disclosure is stated to be confidential or proprietary prior to disclosure and is reduced to writing and given to the Receiving Party in written form within thirty (30) days after the oral disclosure thereof.  Such confidential and proprietary information shall include, without limitation, marketing and sales information, commercialization plans and strategies, research and development work plans, and technical information such as patent applications, inventions, trade secrets, systems, methods, apparatus, designs, tangible material, organisms and products and derivatives thereof.

 

8.3                               Exceptions.  The above obligations of confidentiality and restrictions on use shall not be applicable to the extent:

 

a)                                     such information is general public knowledge or, after disclosure hereunder, becomes general or public knowledge through no fault of the Receiving Party;

 

b)                                     such information can be shown by the Receiving Party by its written records to have been in its possession, with no obligation of confidentiality to a Third Party, prior to receipt thereof hereunder;

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

10

 

c)                                      such information is received by the Receiving Party from any Third Party for use or disclosure by the Receiving Party without any obligation of confidentiality or restriction on use, provided, however, that information received by the Receiving Party from any third Party funded by the Disclosing Party (e.g. consultants, subcontractors, etc.) shall not be released from confidentiality under this exception;

 

d)                                     such information was independently developed by the Receiving Party without use of the information of the Disclosing Party; or

 

e)                                      the disclosure of such information s required to comply with or fulfill applicable law or court process, governmental requirements, submissions to governmental bodies, or the securing of regulatory approvals.

 

8.4                               Confidentiality of Agreement.  Each Party shall, to the extent reasonably practicable, maintain the confidentiality of this Agreement and its provisions and shall refrain from making any public announcement or disclosure of the terms of this Agreement without the prior written consent of the other Party, except to the extent a Party concludes in good faith that such disclosure is required under applicable law or regulations, in which case the other Party shall be notified in advance.

 

9.                                      Compliance with Law

 

In exercising any and all rights and in performing its obligations hereunder, LCE shall comply fully with any and all applicable laws, regulations and ordinances and shall obtain and keep in effect all applicable licenses, permits and other governmental approvals, whether at the federal, state or local levels, necessary to perform the Licensed Services and carry on its activities hereunder and LCE hereby agrees to defend, indemnify and hold RMS and its Affiliates harmless from and against any and all liability, demands, damages, expenses (including attorneys’ and experts’ fees) and losses suffered or incurred by RMS or its Affiliates arising from, resulting from or otherwise concerning any breach by LCE of its obligations under this Section 9.  RMS may advise LCE in writing if LCE conducts any activity(ies) in connection with this Agreement that has (or is reasonably likely to have) an adverse effect on the business reputation of RMS, and LCE will have thirty (30) days after receipt of such written notice to correct any such activity(ies).

 

10.                               Assignment

 

This Agreement shall not be assigned or transferred by LCE (including by merger, operation of law or in any other manner including, without limitation, any purported assignment or transfer that might arise from a sale or transfer of LCE’s business or assets) without the express written consent of RMS.  RMS may assign all or any part of its rights and obligations under this Agreement at any time without the consent of LCE.  LCE agrees to execute such further acknowledgments or other instruments as RMS may reasonably request in connection with any such assignment.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

11

 

11.                               Negation of Warranties and Indemnity

 

11.1                        Nothing in this Agreement shall be construed as:

 

a)                                     a warranty or representation by RMS as to the validity or scope of any patent included within the Licensed Technology;

 

b)                                     a warranty or representation that the use of the Licensed Technology and/or the performance of Licensed Services are or will be free from infringement of patents of Third Parties;

 

c)                                      an obligation to bring or Prosecute actions or suits against Third Parties for infringement; or

 

d)                                     conferring by implication, estoppel or otherwise any license, right or immunity under any patents or patent applications of RMS other than those patents specified in Licensed Technology, regardless of whether such other patents and applications are dominant or subordinate to the patents in Licensed Technology.

 

11.2                        RMS MAKES NO EXPRESS OR IMPLIED WARRANTIES Of MERCHANTABITITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

 

11.3                        LCE shall assume full responsibility for its use of the Licensed Technology and shall defend, indemnify and hold RMS and its Affiliates harmless from and against all liability, demands, damages, expenses (including attorneys’ and experts’ fees) and losses for death, personal injury, illness, errors, property damage or any other injury or damage, including any damages or expenses arising in connection with state or federal regulatory action (collectively “Damages”), arising or resulting from or otherwise concerning the use by LCE, including its officers, directors, agents and employees, of the Licensed Technology or the performance of the Licensed Services,, except, and only to the extent that such Damages are caused solely by the negligence or willful misconduct of RMS.

 

12.                               General

 

12.1                        Entire Agreement.  This Agreement constitutes the entire agreement between The Parties as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings are merged into, extinguished by and completely expressed by it.  This Agreement may be modified or amended only by a writing executed by an authorized officer of each of The Parties.

 

12.2                       Notice.  Any notice required or permitted to be sent hereunder shall be given by hand delivery, by registered, express or certified mail, return receipt requested, postage prepaid, or by nationally recognized private express courier or by confirmed facsimile to the other

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

12

 

Party at the address listed below, or to such other addresses of which a Party may so notify the other.  Notices will be deemed given when hand delivered if by hand delivery, or when received if by any other authorized method.

 

	
If   to RMS:
    	
Roche   Molecular Systems, Inc.
    
	
 
    	
4300   Hacienda Drive
    
	
 
    	
Pleasanton,   California 94588
    
	
 
    	
Attn:   Licensing Department
    
	
 
    	
 
    
	
RMS   cc:
    	
Roche   Molecular Systems, Inc.
    
	
 
    	
4300   Hacienda Drive
    
	
 
    	
Pleasanton,   California 94588
    
	
 
    	
Attn:   General Counsel
    
	
 
    	
 
    
	
If   to LCE:
    	
CardioDx, Inc.
    
	
 
    	
2500   Faber Place
    
	
 
    	
Palo   Alto, CA 94303
    
	
 
    	
Attn:   Chief Executive Officer
    

 

12.3                        Governing Law.  This Agreement is subject to and shall be construed and enforced in accordance with the law of the State of California, U.S.A., excluding its conflict of laws rules and except as to any issue concerning the validity, scope or enforceability of any patent within the Licensed Technology, which issue shall be determined in accordance with the applicable patent laws of the United States.

 

12.4                        Arbitration.  All disputes, claims or controversies arising between the Parties concerning this Agreement or the matters or transactions contemplated herein shall be settled by final and binding arbitration conducted in San Francisco, California pursuant to the Commercial Arbitration Rules of the American Arbitration Association, in accordance with the following procedural process:

 

a)                                     The arbitration tribunal shall consist of three arbitrators.  In the request for arbitration and the answer thereto, each Party shall nominate one arbitrator and the two arbitrators so named will then jointly appoint a third neutral arbitrator as chairman of the arbitration tribunal.  If the two arbitrators so named are unable to appoint a third neutral arbitrator, the third neutral arbitrator shall be appointed by the American Arbitration Association in accordance with the procedures contained in the Commercial Arbitration Rules.

 

b)                                     The decision of the arbitration tribunal shall be final and binding and judgment upon such decision may be entered in any court of competent jurisdiction for judicial acceptance of such an award and enforcement.  Each Party hereby submits itself to the jurisdiction of the courts of the place of arbitration, but only for the entry of judgment with respect to the decision of the arbitrators hereunder.

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

13

 

12.5                        No Conflict with Law.  Nothing in this Agreement shall be construed so as to require the commission of any act contrary to law, and wherever there is any conflict between any provision of this Agreement or concerning the legal right of The Parties to enter into this Agreement and any statute, law, ordinance or treaty, the latter shall prevail, but in such event the affected provisions of the Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal requirements.  In any event, all other provisions of this Agreement shall be deemed valid and enforceable to the fullest extent possible.

 

12.6                        Superceding Agreement.  Concurrent with the execution of this Agreement, and effective as of the Effective Date herein, any existing agreement between The Parties which grants rights to PCR technology to LCE to perform human diagnostic testing services, is hereby superceded and replaced in its entirety by ‘this Agreement.

 

12.7                        Waiver.  Neither the waiver by either of The Parties hereto of a breach of or a default under any of the provisions of this Agreement, not the failure of either of The Parties, on one or more occasions, to enforce any of the provisions of this Agreement, or to exercise any right or privilege hereunder thereafter be cons1rued as a waiver of any Subsequent breach or default of a similar nature, or as a waiver of any such provisions, rights, or privileges hereunder.

 

12.8                        Headings.  The section headings used in this Agreement are intended principally for convenience and shall not by themselves, determine the rights and obligations of the Parties to this Agreement.

 

IN WITNESS WHEREOF, The Parties hereto have set their hands and seals and duly executed this Agreement on the date(s) indicated below, to be effective as of the Effective Date as defined herein.

 

	
ROCHE MOLECULAR SYSTEMS, INC.
    	
CARDIODX, INC.
    
	
 
    	
 
    
	
By:   
    	
/s/   Ruedi Stoffel
    	
 
    	
By:   
    	
/s/   David Levison
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:   
    	
Ruedi   Stoffel
    	
 
    	
Name:   
    	
David   Levison
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:   
    	
Head   of Business Development and Strategic Planning
    	
 
    	
Title:   
    	
President   and CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:   
    	
Nov. 3,   2008
    	
 
    	
Date:   
    	
Oct. 28,   2008
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

14

 

ATTACHMENT I

Licensed Technology

 

	
USP   4,946,952
    	
 
    	
Process   for isolating nucleic acids
    
	
USP   5,057,410
    	
 
    	
Chimeric   messenger RNA detection methods
    
	
USP   5,063,162
    	
 
    	
Process   for isolating nucleic acids utilizing protease digestion
    
	
USP   5,066,584
    	
 
    	
Methods   for generating single stranded DNA by the polymerase chain reaction
    
	
USP   5,075,216
    	
 
    	
Methods   for DNA sequencing with thermus aquaticus DNA polymerase
    
	
USP   5,091,310
    	
 
    	
Structure-independent   DNA amplification by the polymerase chain reaction
    
	
USP   5,110,920
    	
 
    	
HLA   typing method and DNA probes used therein
    
	
USP   5,210,015
    	
 
    	
Homogeneous   assay system using nuclease activity of a nucleic acid polymerase
    
	
USP   5,219,727
    	
 
    	
Quantitation   of nucleic acids using the polymerase chain reaction
    
	
USP   5,310,652
    	
 
    	
Reverse   transcription with thermostable DNA polymerase — high temperature reverse   transcription
    
	
USP   5,310,893
    	
 
    	
Method   for HLA DP typing
    
	
USP   5,314,809
    	
 
    	
Methods   for nucleic acid amplification
    
	
USP   5,322,770
    	
 
    	
Reverse   transcription with thermostable DNA polymerases — high temperature reverse   transcription
    
	
USP   5,389,512
    	
 
    	
Method   for determining the relative amount of a viral nucleic acid segment in a   sample by the polymerase chain reaction
    
	
USP   5,407,800
    	
 
    	
Reverse   transcription with thermus thermophilus polymerase
    
	
USP   5,411,876
    	
 
    	
Use   of grease or wax in the polymerase chain reaction
    
	
USP   5,418,149
    	
 
    	
Reduction   of non-specific amplification glycosylase using dutp and DNA uracil
    
	
USP   5,451,505
    	
 
    	
Methods   for tagging and tracing materials with nucleic acids
    
	
USP   5,451,512
    	
 
    	
Methods   and reagents for HLA Class I A locus DNA typing
    
	
USP   5,468,613
    	
 
    	
Process   for detecting specific nucleotide variations and genetic polymorphisms   present in nucleic acids (kit claims excluded)
    
	
USP   5,476,774
    	
 
    	
Quantitation   of nucleic acids using the polymerase chain reaction (kit claims excluded)
    
	
USP   5,487,972
    	
 
    	
Nucleic   acid detection by the 5’-3’ exonuclease activity of polymerases acting on   adjacently hybridized oligonucleotides
    
	
USP   5,491,063
    	
 
    	
Methods   for in-solution quenching of fluorescently labeled oligonucleotide probes
    
	
USP   5,541,065
    	
 
    	
Method   for HLA DP typing (kit claims excluded)
    
	
USP   5,501,963
    	
 
    	
Amplification   of nucleic acids in blood samples
    
	
USP   5,508,168
    	
 
    	
Methods   and reagents for the detection of herpes simplex virus, treponema pallidum   and haemophilus ducreyi
    
	
USP   5,543,296
    	
 
    	
Detection   of carcinoma metastases by nucleic acid amplification
    
	
USP   5,550,039
    	
 
    	
Oligonucleotide   primers for HLA Class I B locus DNA typing (kit claims excluded)
    
	
USP   5,561,058
    	
 
    	
Methods   for coupled high temperatures reverse transcription and polymerase chain   reactions
    
	
USP   5,565,339
    	
 
    	
Compositions   and methods for inhibiting dimerization of primers during storage of   polymerase chain reaction reagents
    
	
USP   5,567,809
    	
 
    	
Methods   and reagents for HLA DR beta DNA typing
    
	
USP   5,571,673
    	
 
    	
Methods   for in-solution quenching of fluorescently labeled olignucleotide probes
    
	
USP   5,573,906
    	
 
    	
Detection   of nucleic acids using a hairpin forming oligonucleotide primer and an energy   transfer detection system (kit claims excluded)
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

1

 

	
USP   5,604,099
    	
 
    	
Process   for detecting specific nucleotide variations and genetic polymorphisms   present in nucleic acids (kit claims excluded)
    
	
USP   5,614,388
    	
 
    	
PCR   primers for detection of legionella species and methods for controlling   visual intensity hybridization assays
    
	
USP   5,618,703
    	
 
    	
Unconventional   nucleotide substitution in temperature selective rt-PCR   (reverse-transcription PCR)
    
	
USP   5,620,847
    	
 
    	
Methods   and reagents for detection of bacteria in cerebrospinal fluid
    
	
USP   5,635,348
    	
 
    	
Method   and probes for identifying bacteria found in blood
    
	
USP   5,643,723
    	
 
    	
Detection   of a genetic locus encoding resistance to rifampin in mycobacterial cultures   and in clinical specimens
    
	
USP   5,643,724
    	
 
    	
Methods   and reagents for glycophorin A typing
    
	
USP   5,665,548
    	
 
    	
Characterization   and detection of sequences associated with autoimmune diseases
    
	
USP   5,677,152
    	
 
    	
Amplification   using a reversibly inactivated thermostable enzyme (method and reaction   mixture claims only)
    
	
USP   5,693,517
    	
 
    	
Reagents   and methods for coupled high temperature reverse transcription and polymerase   chain reactions
    
	
USP   5,766,888
    	
 
    	
Detection   of carcinoma metastases by nucleic acid amplification
    
	
USP   5,773,258
    	
 
    	
Nuclease   acid amplification using a reversibly inactivated thermostable enzyme (method   claims only)
    
	
USP   5,804,375
    	
 
    	
Reaction   mixtures for detection of target nucleic acids (kit claims excluded)
    
	
USP   5,912,117
    	
 
    	
Method   for diagnosis of lyme disease
    
	
USP   5,994,056
    	
 
    	
Homogeneous   methods for nucleic acid amplification and detection
    
	
USP   6,127,155
    	
 
    	
Stabilized   thermostable nucleic acid polymerase compositions containing non-ionic   polymeric detergents
    
	
USP   6,171,785
    	
 
    	
Methods   and devices for homogeneous nucleic acid amplification and detection
    
	
USP   6,174,670
    	
 
    	
Monitoring   amplification of DNA during PCR
    
	
USP   6,194,561
    	
 
    	
Characterization   and detection of sequences associated with autoimmune diseases
    
	
USP   6,569,627
    	
 
    	
Monitoring   hybridization during PCR using SYBRTM Green I
    
	
USP   6,664,046
    	
 
    	
Quantification   of hTERT mRNA expression
    
	
USP   6,656,691
    	
 
    	
TCF-1   nucleotide sequence variation
    
	
USP   6,933,119
    	
 
    	
Methods   and compositions for the detection and treatment of multiple sclerosis
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

2

 

ATTACHMENT II

 

COMBINATION SERVICES

 

	
Licensed Service(s)
    	
 
    	
Percent of Net Service
   Revenues for Combination
   Services which is Attributable
   to Licensed Services)
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
[...*...]
    	
 
    	
[...*...]
    	
 
    

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

ATTACHMENT III

 

SUMMARY ROYALTY REPORT

 

for the Period                          to                         

 

	
Licensee:   CardioDx, Inc.
    	
 
    	
Field   of Use: human in vitro services
    
	
Effective   Date:
    	
 
    	
Royalty   Rate: [... * ...]
    

 

	
Licensed Service
   (“Lic. Service”)
    	
Number of
   Lic.
   Services
   Performed
    	
Gross
   Invoice
   Price per
   Lic.
   Service
    	
Allowed
   Deductions
    	
Combination
   Service % (see
   Attach II)
   *
    	
Net
   Service
   Revenue
    	
Earned
   Royalty
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TOTALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

Check here if there were no Licensed Services performed for this report period:

 

* Combination Service %s must be previously agreed upon.  To confirm that a Combination Service % has been established or to propose this status, please contact RMS Licensing at (925) 730-8553.

 

I hereby certify the information set forth above is correct and complete with respect to the amounts due under the applicable license agreement

 

	
By:
    	
 
    	
 
    	
Title:
    	
 
    
	
(authorized signature)
    	
 
    	
 
    
	
Name   (please print):
    	
 
    	
 
    	
Date:
    	
 
    
						

 

Mail report with any royalty payment due to:

Roche Molecular Systems, Inc., P.O. Box 120216, Dallas, TX 75312-0216

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

ATTACHMENT IV

 

COLLECTION RATE

 

	
Fiscal Year
    	
 
    	
Collection Rate Percentage
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    

 

[Only applicable as provided in Section 4.2]

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

ATTACHMENT III

 

SUMMARY ROYALTY REPORT

 

for the Period                          to                        

 

	
Licensee:   CardioDx, Inc.
    	
 
    	
Field   of Use: human in vitro services
    
	
Effective   Date: November 3, 2008
    	
 
    	
Royalty   Rate: [... * ...]
    
	
Roche   Contract: RMS-19004
    	
 
    	
 
    

 

	
Licensed Service
   (“Lic. Service”)
    	
Number of
   Lic.
   Services
   Performed
    	
Gross
   Invoice
   Price per
   Lic.
   Service
    	
Allowed
   Deductions
    	
Combination
   Service % (see
   Attach II)
   *
    	
Net
   Service
   Revenue
    	
Earned
   Royalty
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TOTALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

Check here if there were no Licensed Services performed for this report period:

 

* Combination Service %s must be previously agreed upon.  To confirm that a Combination Service % has been established or to propose this status, please contact RMS Licensing at (925) 730-8553.

 

I hereby certify the information set forth above is correct and complete with respect to the amounts due under the applicable license agreement

 

	
By:
    	
 
    	
 
    	
Title:
    	
 
    
	
(authorized signature)
    	
 
    	
 
    
	
Name   (please print):
    	
 
    	
 
    	
Date:
    	
 
    
						

 

Mail report with any royalty payment due to:

Roche Molecular Systems, Inc., P.O. Box 120216, Dallas, TX 75312-0216

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

LICENSEE CONTACT INFORMATION

 

Licensee Name:                                                         CardioDx, Inc.

 

Contract #:                                                                                  RMS-19004

 

Effective Date:                                                             November 3, 2008

 

	
Financial Contact (for Royalty Reports)
    	
 
    
	
Name:
    	
Direct   Phone Number: ( )
    
	
Title:
    	
Fax   Number(s): ( )
    
	
Address:
    	
City:
    
	
State:   
    	
Zip:
    	
email
    
	
 
    	
 
    
	
Contact For Technical Questions
    	
 
    
	
Name:
    	
Direct   Phone Number: ( )
    
	
Title:
    	
Fax   Number(s): ( )
    
	
Address:
    	
City:
    
	
State:   
    	
Zip:
    	
email
    
	
 
    	
 
    
	
Notice Contact
    	
 
    
	
Name:
    	
Direct   Phone Number: ( )
    
	
Title:
    	
Fax   Number(s): ( )
    
	
Address:
    	
City:
    
	
State:   
    	
Zip:
    	
email
    
	
 
    	
 
    
	
Administrative Assistant to Notice Contact
    	
 
    
	
Name:
    	
Direct   Phone Number: ( )
    
	
Title:
    	
 
    
	
Person Completing This Form
    	
 
    
	
Name:
    	
Direct   Phone Number: ( )
    
	
Title:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    

 

Please return the completed form to:

Roche Molecular Systems, Inc.

4300 Hacienda Drive

Pleasanton, CA 94566-0900

Attn:  Licensing Manager

Fax:  (926) 730-8992

donna.donohue@roche.com

 

[...*...] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]